The cellular mechanisms behind the additive effect of combination therapy involve increases in the fraction and effector functions of CD8, Th1 and NK cells, decreases in the fraction of Treg cells, increases in the fraction of DC1 and M1 macrophages, and increases in the number of tumor-antigen-specific T cells in the peripheral lymphoid organs. This evidence concerns the gene CD8A and neoplasm.